Mini ReviewOpen Access

Updated Palliative Chemotherapy for Biliary Tract Cancer

Volume 2 - Issue 2

Jun Ho Ji¹ and Jung-Hun Kang²*

Author Information Open or Close
- ¹Division of Hematology and Oncology, Department of Internal Medicine, Sungkyunkwan University Scholl of Medicine, South Korea
- ²Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, South Korea
*Corresponding author: Jung-Hun Kang, Department of Internal Medicine, Gyeongsang National University College of Medicine, 79 Gangnam-ro, S-Korea

Received: January 25, 2018; Published: February 06, 2018

DOI: 10.26717/BJSTR.2018.02.000731

Full Text PDF

To view the Full Article Peer-reviewed Article PDF

Abstract

Biliary tract cancer (BTC) is rare and often diagnosed at an advanced stage. Thus, palliative treatment is usually the only option for patients with advanced biliary tract cancer. Many chemotherapeutic agents have been tested. However, few therapeutic medications have been proven to be useful. With the recent increase in the understanding of drug resistance mechanisms and molecular features of cancer cells, possible new drugs are emerging. Herein, we discuss issues including the choice of chemotherapy and optimal chemotherapy and categorizing treatment types into cytotoxic chemotherapy, targeted therapy, and immunotherapy.

Keywords: Biliary Tract Cancer; Palliative Chemotherapy

Abstract| Introduction| Conclusion| References|